Richard Bleicher named chief of new Division of Breast Surgery at Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Richard Bleicher

Richard Bleicher, a professor in the Department of Surgical Oncology and clinical director of the Breast Service Line, has been promoted to chief of the new Division of Breast Surgery at Fox Chase Cancer Center. 

The newly formed Division of Breast Surgery was created to focus efforts at Fox Chase on increasing access for breast cancer patients, as well as on clinical trials and research. In his new role, Bleicher will oversee the division’s programs, research portfolio, and all clinical activities. Additionally, he will provide support for the recruitment of new faculty and the growth of the breast program at all Fox Chase satellite campuses, as well as lead and manage the division. 

Bleicher has been instrumental in expanding the breast faculty within the department and growing the breast surgical program in volume, location, and scope. He will continue to serve as the clinical director of the Breast Service Line at Fox Chase, a position he has held since June 2023. 

Bleicher specializes in breast cancer with a focus on novel treatment modalities, clinical trials, and cosmetic outcomes, but he is most highly recognized and cited for his research regarding the impact of timeliness and delays on breast cancer treatment. His work is the basis for two current Commission on Cancer national quality measures. 

He frequently deals with cases that are not commonly seen by other clinicians, including unusual pathology results, complex cases, and rare clinical situations such as male breast cancer. His research interests include health services research, breast imaging, population studies, sentinel node biopsy in breast cancer, and disparities in breast cancer, among others. 

Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial. 
Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.
From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center,  a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login